Sunday, May 11

Alert The Elanians: A Bull's On The Loose

Don't look now, but in the first week of the new year shares of Elan are up 30 percent. ELN stock lost nearly three-quarters of its value last year on safety concerns about the multiple sclerosis drug Tysabri, which it shares with Biogen Idec, and efficacy concerns over the Alzheimer's drug it's developing with Wyeth.
Pharma's Market - CNBC